ImmuCell Q3 preliminary sales $5.4M (+13% YoY); backlog rises to $8.9M

IMMUCELL CORP /DE/

2023-Q3 EPS reported -$0.60 revenue$12,375,708

Q3 2023 total sales $5.40M, up 13% from $4.80M in Q3 2022.
Nine-month sales $12.38M, down 16% YoY; trailing twelve months $16.29M, down 19%.
Finished goods production in Q3 was $5.3M, approximately 89% of the $6M quarterly goal.
Order backlog increased to $8.9M from $8M at June 30, 2023 and $2.5M at Dec 31, 2022.
Company overcame earlier contamination events; third FDA submission for Re-Tain under 6-month review.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

IMMUCELL CORP /DE/ reported quarter ended September 30, 2023 results: revenue $5.40 million.

Period: quarter ended September 30, 2023
Revenue: $5.40 million
Result: preliminary results

Exact text from the filing

September 30, 2023. Preliminary, Unaudited Total Sales Results: 2023 2022 $ Increase ($ Decrease) % Increase (% Decrease) During the Three-Month Periods Ended September 30, $ 5.40 million $ 4.80 million $ 600,000 13 % During the Nine-Month Periods Ended September 30, $ 12.38 million $ 14.66 million $ (2.28 million ) (16 %) During the Trailing Twelve-Month Periods

View on SEC.gov

Browse all earnings releases →

IMMUCELL CORP /DE/ filing history →

Source: SEC EDGAR

accession 0001013762-23-002136

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.